Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Animal genetics company Genus said a US court ruled that ABS Global's sales of the Genus' sexing semen technology under the IntelliGen brand had infringed three patents asserted by Inguran and Cytonome.
On 9 September 2019, the jury held that the IntelliGen technology infringed the '987 patent along with US patents 7,311,476 and 7,611,309 and that Inguran and Cytonome/ST collectively known as ST were not in material breach of the 2012 Semen Sorting Agreement between the parties.
The infringement of the '987 patent confirmed ABS' existing obligation to pay a royalty of $1.25 for each straw of sexed semen produced in the US, the company said.
The jury would now consider damages that flow from the infringement of the '476 and '309 patents. ABS, meanwhile, was considering its options for appeal, the company added.
The litigation, part of a long-running dispute since 2014 between ABS and ST concerning the development and launch of Genus' sexed semen technology -- a proprietary product which competes with ST in the market for processing sexed bovine semen.
At 9:00am: (LON:GNS) Genus PLC share price was -29p at 2801p